Financial Calendar Update - Coloplast has updated the publication dates for its FY Financial Statements 2025/26 and the Annual General Meeting 2026, with the Financial Statements now scheduled for November 3, 2026, instead of November 5, 2026, and the Annual General Meeting moved to December 1, 2026, from December 3, 2026 [2][3] Company Background - Coloplast was founded in 1954, inspired by a nurse, Elise Sørensen, who developed the first adhesive ostomy bag to help her sister after an ostomy operation. This innovation has allowed millions to live more independent lives [5]

Leadership Changes - Coloplast is announcing changes to its Executive Leadership Team (ELT), specifically in the Interventional Urology business and the global People & Culture function [1] - Dorthe Rønnau, Executive Vice President of People & Culture, will leave the company after nearly three decades to pursue other opportunities [1][2] - An external search is underway for a new leader for the global People & Culture function, with Mads Mikkelsen taking over interim leadership until a permanent successor is found [3] Retirement and Succession - Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year after over a decade with Coloplast and more than thirty years in the global life science industry [4] - Kevin Hardage will assume the role of Executive Vice President of Interventional Urology starting February 9th, bringing extensive experience from the global MedTech industry [6] - There will be an overlap period between Tommy Johns and his successor to ensure a thorough handover [5] Leadership Perspectives - Lars Rasmussen, interim CEO of Coloplast, praised both Dorthe Rønnau and Tommy Johns for their contributions and expressed confidence in Kevin Hardage's ability to lead the Interventional Urology business into a new growth phase [7]

Core Points - The Annual General Meeting of Coloplast A/S is scheduled for December 4, 2025, at 3:30 pm CET in Humlebæk, Denmark [1] - Coloplast A/S has a history dating back to 1954, originating from a nurse's idea to create the first adhesive ostomy bag [4] - The company focuses on developing products and services that enhance the independence of individuals with various medical needs [6] Company Information - Coloplast A/S is headquartered at Holtedam 1, DK-3050 Humlebaek, Denmark, and is registered under company reg. (CVR) no. 69749917 [3] - The company operates in multiple business areas, including Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology [6] - The Coloplast logo is a registered trademark, and all rights are reserved by Coloplast A/S [7]

Core Insights - The company reported a 3% increase in revenue to DKK 27,874 million for FY 2024/25, with an organic growth of 7% and an EBIT margin of 28% [1][8] - The Board of Directors proposed a year-end dividend of DKK 18.00 per share, raising the total dividend for the year to DKK 23.00 per share, compared to DKK 22.00 per share last year [2] Financial Performance - EBIT for FY 2024/25 was DKK 7,670 million, reflecting a 5% increase from the previous year, with an EBIT margin improvement from 27% to 28% [8] - Adjusted net profit before special items was DKK 5,148 million, an increase of DKK 123 million from last year, with adjusted diluted EPS before special items rising by 2% to DKK 22.84 [8] - The adjusted free cash flow-to-sales ratio improved to 19% from 15% last year [8] Business Segments - Organic growth rates by business area were as follows: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8%, and Interventional Urology 2% [1] Special Items and Expenses - Special items expenses totaled DKK 469 million, related to profitability improvement initiatives, including the Skin Care divestment and management restructuring [2] Sustainability Initiatives - Production waste recycling increased to 83% in FY 2024/25, surpassing the 2025 target of 75% [3] - Scope 1 and 2 emissions decreased by 41% compared to the base year 2018/19, a significant improvement from the previous year's reduction of 22% [4] Future Guidance - For FY 2025/26, the company anticipates around 7% organic revenue growth and EBIT growth in constant currencies, with a return on invested capital expected to be around 16% [5][6] - Reported growth in DKK is projected at 4-5%, with a negative impact from currencies and the skin care divestment [5]